The cardioprotective effects of Carvedilol (cas 72956-09-3) on ischemia and reperfusion injury by AMPK signaling pathway
-
Add time:07/15/2019 Source:sciencedirect.com
Carvedilol (cas 72956-09-3), a third generation beta blocker, is in clinical use for heart failure patients. However, besides adrenergic receptor blockade, the pharmacological effects of carvedilol on cardiomyocytes remain unknown. AMP-activated protein kinase (AMPK) is an emerging target recognized for heart failure treatment. The mechanical properties and intracellular Ca2+ properties were measured in isolated cardiomyocyte contractile functions in response to ischemic stress. Treatment of cardiomyocytes with carvedilol augmented phosphorylation of AMPK and downstream acetyl CoA carboxylase (ACC), and ameliorated hypoxia-induced impairment in maximal velocity of shortening (+dL/dt) and relengthening (-dL/dt), and the impaired peak height and peak shortening (PS) amplitude caused by hypoxia. Carvedilol treatment improved calcium homeostasis with rescuing the peak Ca2+ signal, the maximum rate of Ca2+ change during contraction (+dF/dt) and the maximum rate of Ca2+ change during relaxation (-dF/dt) under hypoxia conditions. In mouse hearts perfused ex vivo with carvedilol, the function of post-ischemia left ventricle was improved and an augmentation in myocardial glucose uptake and glucose oxidation, and inhibition of fatty acid oxidation during ischemia and reperfusion. The protective effect of carvedilol was further supported in an in vivo regional ischemia model by ligation of left anterior descending coronary artery (LAD), mice treated with carvedilol followed by LAD occlusion and reperfusion showed significant size reduction in infarcted myocardium and improved cardiac functions. Therefore, Carvedilol as a clinical drug can modulate cardiac AMPK signaling pathway to reduce ischemic insults by ischemia and reperfusion.
We also recommend Trading Suppliers and Manufacturers of Carvedilol (cas 72956-09-3). Pls Click Website Link as below: cas 72956-09-3 suppliers
Prev:Carvedilol (cas 72956-09-3) blockage of delayed rectifier Kv2.1 channels and its molecular basis
Next:Soluplus®, Eudragit®, HPMC-AS foams and solid dispersions for enhancement of Carvedilol (cas 72956-09-3) dissolution rate prepared by a supercritical CO2 process) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Enhancement of oral bioavailability of poorly water soluble Carvedilol (cas 72956-09-3) by chitosan nanoparticles: Optimization and pharmacokinetic study07/22/2019
- Solidification of Carvedilol (cas 72956-09-3) loaded SMEDDS by swirling fluidized bed pellet coating07/20/2019
- Prophylactic use of Carvedilol (cas 72956-09-3) to prevent ventricular dysfunction in patients with cancer treated with doxorubicin07/21/2019
- Carvedilol (cas 72956-09-3) attenuates experimentally induced silicosis in rats via modulation of P-AKT/mTOR/TGFβ1 signaling07/19/2019
- Carvedilol (cas 72956-09-3) and thyroid hormones co-administration mitigates oxidative stress and improves cardiac function after acute myocardial infarction07/18/2019
- Comparative study of Carvedilol (cas 72956-09-3) and quinidine for inhibiting hKv4.3 channel stably expressed in HEK 293 cells07/17/2019
- Soluplus®, Eudragit®, HPMC-AS foams and solid dispersions for enhancement of Carvedilol (cas 72956-09-3) dissolution rate prepared by a supercritical CO2 process07/16/2019
- Carvedilol (cas 72956-09-3) blockage of delayed rectifier Kv2.1 channels and its molecular basis07/14/2019
- The adrenergic receptor antagonist Carvedilol (cas 72956-09-3) interacts with serotonin 2A receptors both in vitro and in vivo07/13/2019
-
Health and Chemical more >
-
Related Products